Neglected Tropical Disease Mycetoma Research Gains Momentum
Patients outside the Mycetoma Research Center in Sudan. Credit: DNDi By Geoffrey KamadiNAIROBI, Apr 7 2023 (IPS) The disease burden and distribution of mycetoma—a neglected tropical disease—are not very well understood. However, it is known to affect people in Sudan, Senegal, Mauritania, Kenya, and Niger, as well as people in Nigeria, Ethiopia, India, and Cameroon. Cases have also been reported in Djibouti, Somalia, and Yemen.
“It is currently unknown what the incidence, prevalence and the number of reported cases per year per country is,” observes Dr Borna Nyaoke, head of the Mycetoma Program at the Drugs for Negl...
Source: IPS Inter Press Service - Health - April 7, 2023 Category: International Medicine & Public Health Authors: Geoffrey Kamadi Tags: Africa Featured Headlines Health Inequity TerraViva United Nations IPS UN Bureau IPS UN Bureau Report Kenya Sudan Source Type: news
Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
RARITAN, NJ, March 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 A DUE study (NCT03904693), which showed an investigational once-daily, single tablet combination therapy, also known as fixed dose combination, of macitentan 10 mg and tadalafil 40 mg (M/T STCT), significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in pulmonary arterial hypertension (PAH) patients with World Health Organization (WHO) functional class (FC) II or III.[1] The data were presented today as a Late-...
Source: Johnson and Johnson - March 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meeting
TITUSVILLE, N.J. – October 14, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual meeting of the American College of Chest Physicians, held virtually October 17-20.Data presentations from eight abstracts will provide additional evidence supporting the role of objective multiparameter risk assessment approaches in helping to optimize treatment and care for pulmonary arterial hypertension (PAH), as well as the impact of earlier and comprehensive therapy with UPTRAVI...
Source: Johnson and Johnson - October 14, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Kuric (ketoconazole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 27, 2020 Category: Drugs & Pharmacology Source Type: news
Metronidazole vs. Ketoconazole
Title: Metronidazole vs. KetoconazoleCategory: MedicationsCreated: 11/11/2019 12:00:00 AMLast Editorial Review: 11/11/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 11, 2019 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death
[05-19-2016] The U.S. Food and Drug Administration (FDA) is warning health care professionals to avoid prescribing the antifungal medicine ketoconazole oral tablets to treat skin and nail fungal infections. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 2, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Metyrapone supply issue update
Current UK stock of 250 mg metyrapone capsules remains low and is at risk of running out before the next anticipated UK delivery, which should arrive at the end of July.
HRA Pharma have asked for orders to be based on immediate need only and for prescriptions to be limited to only weeks at a time for this short, interim period.
In the event of the product becoming temporarily unavailable please consider licenced alternative options such as Ketoconazole HRA® (ketoconazole tablets 200 mg).
Further information regarding ketoconazole is available atwww.medicines.org.uk/e...
Source: Society for Endocrinology - July 18, 2019 Category: Endocrinology Source Type: news
ketoconazole, Nizoral, Extina, Xolegel, Kuric
Title: ketoconazole, Nizoral, Extina, Xolegel, KuricCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/8/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - July 8, 2019 Category: Dermatology Source Type: news
FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems
The U.S. Food and Drug Administration (FDA) is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug ’s use, warning that it can cause severe liver injuries and adrenal gland problems and advising that it can lead to harmful drug interactions with other medications. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Ketoconazole Cream (Nizoral) vs. Miconazole (Monistat)
Title: Ketoconazole Cream (Nizoral) vs. Miconazole (Monistat)Category: MedicationsCreated: 6/4/2019 12:00:00 AMLast Editorial Review: 6/4/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 4, 2019 Category: Drugs & Pharmacology Source Type: news
Ketoconazole Cream vs. Lamisil (terbinafine)
Title: Ketoconazole Cream vs. Lamisil (terbinafine)Category: MedicationsCreated: 6/3/2019 12:00:00 AMLast Editorial Review: 6/3/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 3, 2019 Category: Dermatology Source Type: news
